Analyst Reco. Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
19.74 ^USD	+4.28%		-4.91%	-15.46%

08/03	Akero Therapeutics Raises $367 Million From Share Offering	MT
07/03	Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Akero Therapeutics Price Target to $42 From $39, Maintains Buy Rating	05/03	MT
HC Wainwright Raises Price Target on Akero Therapeutics to $50 From $43, Maintains Buy Rating	05/03	MT
UBS Adjusts Akero Therapeutics Price Target to $39 From $83, Maintains Buy Rating	12/23/12	MT
Cantor Fitzgerald Cuts Price Target on Akero Therapeutics to $39 From $69, Maintains Overweight Rating	11/23/11	MT
Morgan Stanley Cuts Price Target on Akero Therapeutics to $33 From $70, Maintains Overweight Rating	11/23/11	MT
RBC Cuts Price Target on 89bio to $27 From $34 Amid 'Negative Read-Through' From 'Disappointing' Akero Data; Outperform, Speculative Risk Kept	11/23/11	MT
Cantor Fitzgerald Initiates Akero Therapeutics at Overweight With $69 Price Target	19/23/19	MT
Evercore ISI Raises Price Target on Akero Therapeutics to $60 From $50, Maintains Outperform Rating	13/23/13	MT
UBS Initiates Coverage on Akero Therapeutics With Buy Rating, $83 Price Target	28/23/28	MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	08/23/08	DJ
Morgan Stanley Raises Price Target on Akero Therapeutics to $70 From $65, Maintains Overweight Rating	12/23/12	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Keeps Buy Rating	07/23/07	MT
Canaccord Genuity Adjusts Price Target on Akero Therapeutics to $59 From $58, Maintains Buy Rating	17/23/17	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $62 From $64, Maintains Buy Rating	16/23/16	MT
Canaccord Genuity Adjusts Akero Therapeutics Price Target to $58 From $50, Maintains Buy Rating	20/23/20	MT
Morgan Stanley Upgrades Akero Therapeutics to Overweight From Equal Weight, $65 Price Target	27/23/27	MT
Morgan Stanley Adjusts Price Target on Akero Therapeutics to $40 From $30, Maintains Equalweight Rating	07/22/07	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Maintains Buy Rating	07/22/07	MT
Morgan Stanley Raises Price Target on Akero Therapeutics to $30 From $26, Reiterates Equalweight Rating	14/22/14	MT
Evercore ISI Upgrades Akero Therapeutics to Outperform From In-Line, Adjusts Price Target to $50 From $10	14/22/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Analyst Reco.

Filters